Volume 10, Issue 2 (May 2022)                   Res Mol Med (RMM) 2022, 10(2): 85-96 | Back to browse issues page


XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Ghazaei C. Upcoming Multi-drug-Resistant and Extensively Drug-Resistant Bacteria. Res Mol Med (RMM) 2022; 10 (2) :85-96
URL: http://rmm.mazums.ac.ir/article-1-452-en.html
Department of Microbiology, University of Mohaghegh Ardabili, Ardabil, Iran, P.O. Box 179 , ciamakghazaei@yahoo.com
Abstract:   (2067 Views)
Multi-drug-resistant (MDR) and extensively drug-resistant (XDR) bacteria are becoming a serious global health issue, which may soon become untreatable by clinicians. Since the invention of antibiotics, inappropriate consumption, non-prescribed drugs, overuse, and hoarding have caused the rapid emergence of MDR and XDR bacteria. The ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Pseudomonas aeruginosa, Acinetobacter baumannii, and Enterobacter spp.) cause many nosocomial infections and thus escape the biocidal action of the antibiotic. Gram-positive and Gram-negative bacteria have acquired self-defense tools like ESBL (extended spectrum beta-lactamase), a mutation in porin genes, biofilm production, and many more to develop multi-drug resistance. Antimicrobial resistance (AMR) endangers patients' treatment as it causes high mortality and morbidity rates, economic loss of both patient and country, and prolonged hospital stay. To combat upcoming MDR and XDR bacteria, it is essential to design novel therapeutic techniques to eradicate such resistant bacteria via burgeoning technologies like nanoparticles, CRISPER-Cas9, genetic engineering, and synthetic biology.
 
Full-Text [PDF 873 kb]   (997 Downloads)    
Type of Study: review | Subject: Microbiology
Published: 2022/05/20

Add your comments about this article : Your username or Email:
CAPTCHA

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

 

Designed & Developed by : Yektaweb